0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Recombinant Antibodies > Spike RBD > SAD-S35

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)

  • Description
    Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105).Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
  • Isotype
    Human IgG1/kappa
  • Specificity
    This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain.  No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV,  MERS-CoV,  HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20 to -70°C for 12 months in lyophilized state from date of receipt;

    2. -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE
Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) SDS-PAGE gel

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat.No. SAD-S35) was detected by SARS-CoV-2 Inhibitor screening Kit (Cat.No. EP-105) with a half maximal inhibitory concentration (IC50) of 1.472 μg/mL (QC tested).

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H4) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) with a linear range of 0.2-1.95 ng/mL (QC tested).

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat.No. SAD-S35) was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit (Cat.No. TAS-K022) with a half maximal inhibitory concentration (IC50) of 0.6265 μg/mL (Routinely tested).

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody (Cat. No. SAD-S35) was incubated with  SARS-CoV-2  pseudotyped virus at 37 ℃ for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37 ℃ for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. SAD-S35) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD:ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1 mutant and treated with the antibody at increasing concentration. Percent inhibition is calculated based on the OD value.

Bioactivity-FACS
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag (Cat. No. SPD-C5259) to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35). The concentration of SARS-CoV-2 S protein RBD used is 5μg/ml. The IC50 is 10.33 μg/ml (Routinely tested).

FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag (Cat. No. S1N-C5257) to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35). The concentration of SARS-CoV-2 S1 protein used is 3ug/ml. The IC50 is 1.352 μg/ml (Routinely tested).

Comments (0)

Order Details

Price(USD) : $380.00

Price(USD) : $2500.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop